Lapatinib for the Treatment of Breast Cancer in the People's Republic of China

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2014 Aug 13

PMID 25114575

Citations 7

Authors

Hongjiang Wang

Affiliations

Soon will be listed here.

Abstract

Lapatinib is an oral, small-molecule, reversible inhibitor of both epidermal growth factor receptor and human epidermal growth factor receptor-2 (HER2) tyrosine kinases. In March 2007, the US Food and Drug Administration approved lapatinib for use in combination with capecitabine for the treatment of women with HER2-overexpressing, advanced or metastatic breast cancer. This review discusses the available information of lapatinib in Chinese breast cancer patients, focusing on its effectiveness and clinical application against advanced or metastatic breast cancer. In pivotal phase III trials, a combination of lapatinib and capecitabine significantly decreased the risk of disease progression compared to capecitabine alone in women with HER2-positive advanced or metastatic breast cancer. Other trials were used to evaluate lapatinib in combination with hormone therapy, in combination with trastuzumab, and as an adjunct to adjuvant therapy for early-stage disease. Preclinical data have revealed that lapatinib is active in trastuzumab-resistant cell lines as well as synergistic with trastuzumab. In clinical trials, lapatinib has not been associated with serious or symptomatic cardiotoxicity. Further, it can cross the blood-brain barrier and may therefore have a role in preventing cancer progression in the central nervous system. Thus, lapatinib warrants further evaluation in HER2-positive metastatic and early-stage breast cancer patients.

Citing Articles

Inhibition of the Wnt Signalling Pathway: An Avenue to Control Breast Cancer Aggressiveness.

Castagnoli L, Tagliabue E, Pupa S Int J Mol Sci. 2020; 21(23).

PMID: 33260642 PMC: 7730964. DOI: 10.3390/ijms21239069.

In vitro assessment of the photo(geno)toxicity associated with Lapatinib, a Tyrosine Kinase inhibitor.

Garcia-Lainez G, Vaya I, Marin M, Miranda M, Andreu I Arch Toxicol. 2020; 95(1):169-178.

PMID: 32815004 DOI: 10.1007/s00204-020-02880-6.

BioPATH: A Biomarker Study in Asian Patients with HER2+ Advanced Breast Cancer Treated with Lapatinib and Other Anti-HER2 Therapy.

Kim S, Do I, Tsang J, Kim T, Yap Y, Cornelio G Cancer Res Treat. 2019; 51(4):1527-1539.

PMID: 31163957 PMC: 6790855. DOI: 10.4143/crt.2018.598.

Synthesis of Novel Hybrids of Quinazoline and Artemisinin with High Activities against , Human Cytomegalovirus, and Leukemia Cells.

Frohlich T, Reiter C, Ibrahim M, Beutel J, Hutterer C, Zeittrager I ACS Omega. 2018; 2(6):2422-2431.

PMID: 30023664 PMC: 6044832. DOI: 10.1021/acsomega.7b00310.

The addition of calcitriol or its synthetic analog EB1089 to lapatinib and neratinib treatment inhibits cell growth and promotes apoptosis in breast cancer cells.

Segovia-Mendoza M, Diaz L, Prado-Garcia H, Reginato M, Larrea F, Garcia-Becerra R Am J Cancer Res. 2017; 7(7):1486-1500.

PMID: 28744399 PMC: 5523030.

References

Tripathy D, Slamon D, Cobleigh M, Arnold A, Saleh M, Mortimer J . Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol. 2004; 22(6):1063-70. DOI: 10.1200/JCO.2004.06.557. View

Nahta R, Yu D, Hung M, Hortobagyi G, Esteva F . Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol. 2006; 3(5):269-80. DOI: 10.1038/ncponc0509. View

Montemurro F, Donadio M, Clavarezza M, Redana S, Jacomuzzi M, Valabrega G . Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy. Oncologist. 2006; 11(4):318-24. DOI: 10.1634/theoncologist.11-4-318. View

Chong H, Taib N, Rampal S, Saad M, Bustam A, Yip C . Treatment options for locally advanced breast cancer--experience in an Asian tertiary hospital. Asian Pac J Cancer Prev. 2010; 11(4):913-7. View

Polli J, Olson K, Chism J, John-Williams L, Yeager R, Woodard S . An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib.... Drug Metab Dispos. 2008; 37(2):439-42. DOI: 10.1124/dmd.108.024646. View

Satoh T, Xu R, Chung H, Sun G, Doi T, Xu J . Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study. J Clin Oncol. 2014; 32(19):2039-49. DOI: 10.1200/JCO.2013.53.6136. View

Schluter B, Gerhards R, Strumberg D, Voigtmann R . Combined detection of Her2/neu gene amplification and protein overexpression in effusions from patients with breast and ovarian cancer. J Cancer Res Clin Oncol. 2010; 136(9):1389-400. DOI: 10.1007/s00432-010-0790-2. View

Mok T, Wu Y, Thongprasert S, Yang C, Chu D, Saijo N . Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361(10):947-57. DOI: 10.1056/NEJMoa0810699. View

Shepherd F, Pereira J, Ciuleanu T, Tan E, Hirsh V, Thongprasert S . Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005; 353(2):123-32. DOI: 10.1056/NEJMoa050753. View

10.

Gerstner E, Fine R . Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. J Clin Oncol. 2007; 25(16):2306-12. DOI: 10.1200/JCO.2006.10.0677. View

11.

Goss P, Smith I, OShaughnessy J, Ejlertsen B, Kaufmann M, Boyle F . Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial. Lancet Oncol. 2012; 14(1):88-96. DOI: 10.1016/S1470-2045(12)70508-9. View

12.

Scaltriti M, Verma C, Guzman M, Jimenez J, Parra J, Pedersen K . Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene. 2008; 28(6):803-14. DOI: 10.1038/onc.2008.432. View

13.

Xia W, Husain I, Liu L, Bacus S, Saini S, Spohn J . Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers. Cancer Res. 2007; 67(3):1170-5. DOI: 10.1158/0008-5472.CAN-06-2101. View

14.

Konecny G, Pegram M, Venkatesan N, Finn R, Yang G, Rahmeh M . Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. 2006; 66(3):1630-9. DOI: 10.1158/0008-5472.CAN-05-1182. View

15.

Wiechmann L, Sampson M, Stempel M, Jacks L, Patil S, King T . Presenting features of breast cancer differ by molecular subtype. Ann Surg Oncol. 2009; 16(10):2705-10. DOI: 10.1245/s10434-009-0606-2. View

16.

Dogan E, Yorgun H, Petekkaya I, Ozer N, Altundag K, Ozisik Y . Evaluation of cardiac safety of lapatinib therapy for ErbB2-positive metastatic breast cancer: a single center experience. Med Oncol. 2012; 29(5):3232-9. DOI: 10.1007/s12032-012-0253-5. View

17.

Lee Y, Kim H, Kang M, Cho B, Han S, Kim T . Phosphoproteomic analysis identifies activated MET-axis PI3K/AKT and MAPK/ERK in lapatinib-resistant cancer cell line. Exp Mol Med. 2013; 45:e64. PMC: 3849569. DOI: 10.1038/emm.2013.115. View

18.

Zhou X, Cella D, Cameron D, Amonkar M, Segreti A, Stein S . Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment. Breast Cancer Res Treat. 2009; 117(3):577-89. DOI: 10.1007/s10549-009-0310-8. View

19.

Moy B, Goss P . Lapatinib: current status and future directions in breast cancer. Oncologist. 2006; 11(10):1047-57. DOI: 10.1634/theoncologist.11-10-1047. View

20.

Rusnak D, Affleck K, Cockerill S, Stubberfield C, Harris R, Page M . The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. Cancer Res. 2001; 61(19):7196-203. View